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Noninvasive tumor growth monitoring is of particular interest for the evaluation of
experimental glioma therapies. This study investigates the potential of positron emission
tomography (PET) using O-(2-18F-fluoroethyl)-L-tyrosine ([18F]-FET) to determine tumor
growth in a murine glioblastoma (GBM) model—including estimation of the biological
tumor volume (BTV), which has hitherto not been investigated in the pre-clinical context.
Fifteen GBM-bearing mice (GL261) and six control mice (shams) were investigated during
5 weeks by PET followed by autoradiographic and histological assessments. [18F]-FET
PET was quantitated by calculation of maximum and mean standardized uptake
values within a universal volume-of-interest (VOI) corrected for healthy background
(SUVmax/BG, SUVmean/BG). A partial volume effect correction (PVEC) was applied
in comparison to ex vivo autoradiography. BTVs obtained by predefined thresholds for
VOI definition (SUV/BG: ≥1.4; ≥1.6; ≥1.8; ≥2.0) were compared to the histologically
assessed tumor volume (n = 8). Finally, individual “optimal” thresholds for BTV
definition best reflecting the histology were determined. In GBM mice SUVmax/BG
and SUVmean/BG clearly increased with time, however at high inter-animal variability.
No relevant [18F]-FET uptake was observed in shams. PVEC recovered signal loss
of SUVmean/BG assessment in relation to autoradiography. BTV as estimated by
predefined thresholds strongly differed from the histology volume. Strikingly, the individual
“optimal” thresholds for BTV assessment correlated highly with SUVmax/BG (ρ = 0.97,
p < 0.001), allowing SUVmax/BG-based calculation of individual thresholds. Themethod
was verified by a subsequent validation study (n = 15, ρ = 0.88, p < 0.01) leading to
extensively higher agreement of BTV estimations when compared to histology in contrast
to predefined thresholds. [18F]-FET PET with standard SUV measurements is feasible
for glioma imaging in the GBM mouse model. PVEC is beneficial to improve accuracy
of [18F]-FET PET SUV quantification. Although SUVmax/BG and SUVmean/BG increase
during the disease course, these parameters do not correlate with the respective tumor
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size. For the first time, we propose a histology-verified method allowing appropriate
individual BTV estimation for volumetric in vivomonitoring of tumor growth with [18F]-FET
PET and show that standardized thresholds from routine clinical practice seem to be
inappropriate for BTV estimation in the GBM mouse model.
Keywords: [18F]-FET PET, partial volume effect correction (PVEC), biological tumor volume (BTV), tumor growth
monitoring, orthotopic glioblastoma mouse model (GL261)
INTRODUCTION
The last decade has seen a considerable range of studies
emphasizing the increasing importance of positron emission
tomography (PET) using the radiolabeled amino acid analog
O-(2-[18F]-fluoroethyl)-L-tyrosine ([18F]-FET) for clinical
neuro-oncology (La Fougere et al., 2011; Dunet et al., 2012;
Galldiks et al., 2015b). With precision medicine in mind,
[18F]-FET PET has become of crucial interest especially for
individual therapy management in glioma patients, since it
visualizes the metabolic activity of the glioma-affected brain
tissue and thereby broadens neuroimaging to the molecular
level (Pauleit et al., 2005; Rachinger et al., 2005; Langen et al.,
2006; Dhermain et al., 2010; Galldiks et al., 2012a). Whereas
conventional imaging techniques like structural magnetic
resonance imaging (MRI)—as the current clinical standard for
neuro-oncological imaging—focus on morphologic information,
[18F]-FET PET is a tool to visualize the altered biology of the
tumoral lesion (as compared to non-neoplastic parenchyma) and
promotes a personalized therapy management. In the clinical
setting, [18F]-FET PET has proven its usefulness at primary
diagnosis, e.g. for differential diagnosis (Hutterer et al., 2013;
Rapp et al., 2013), tumor grading (Popperl et al., 2007; Jansen
et al., 2012a; Lohmann et al., 2015), biopsy and treatment
planning (Stockhammer et al., 2009; Plotkin et al., 2010; Kunz
et al., 2011; Tonn et al., 2012), as well as for disease monitoring,
e.g. for response assessment after different therapies (Piroth et al.,
2011; Galldiks et al., 2012b, 2013b), early detection of tumor
recurrence and differentiation from post-therapeutic changes
(Mehrkens et al., 2008; Galldiks et al., 2015a).
While [18F]-FET PET therefore has the potential to play a
more and more important role for neuro-oncology in the clinical
setting, its pre-clinical potential is not yet fully appreciated.
Pre-clinical brain tumor imaging faces similar difficulties as its
clinical equivalent concerning e.g. reliable in vivo volumetry or
bias due to post-therapy effects. Especially damage of the blood
brain barrier (BBB) is a confounding factor for the evaluation
of therapy effects for some of the most promising experimental
therapeutics. Above all, pre-clinical glioma imaging in mouse
models is challenging due to relatively small tumor sizes (of
barely a few cubic millimeters), which require special diligence
to precision imaging and encourage technically sophisticated
methods of image correction.
Altogether, there is a need to improve pre-clinical in vivo
imaging and tumor growth monitoring, when evaluating new
experimental glioma therapies.
Despite the wide clinical use of [18F]-FET PET and in spite
of its above suggested tremendous potential for pre-clinical
research, only few animal studies—generally consisting in tracer
comparisons or focusing on the chemical characteristics of
[18F]-FET—have so far evaluated the performance of [18F]-FET
imaging in rodent glioma models. To the author’s knowledge,
only two pre-clinical reports have so far described the use of
longitudinal [18F]-FET PET for the purpose of brain tumor
growth monitoring—both in the context of relative treatment
response evaluation in xenograft glioblastoma (GBM) mouse
models (Nedergaard et al., 2014, 2015). Studies focusing however
on important methodological aspects of [18F]-FET PET, e.g.
estimation of the biological tumor volume (BTV), are still
lacking.
In this study, on the one hand, we evaluate the general
feasibility of [18F]-FET PET in a murine GBM mouse model
(GL261) using a volume of interest (VOI)-based approach for
image analysis. We apply a partial volume effect correction
(PVEC) to meet the small scale and finally improve accuracy
of standard PET parameters. On the other hand, we aim to
investigate the potential of [18F]-FET PET to reliably determine
the BTV, which hasn’t been investigated so far in the pre-clinical
context. For this purpose, we first translated to our orthotopic
GBM mouse model the clinical approach for BTV estimation
in glioma patients consisting in a semiautomatic threshold-
based VOI-calculation. Second, we evaluated this estimation
by direct comparison of BTV to histologically determined
tumor volume—an approach exclusively subject to pre-clinical
investigations since it is not possible to reliably determine the
histological tumor volume in glioma patients. Finally, we propose
a method for BTV estimation using individual thresholds.
MATERIALS AND METHODS
Cell Culture
GL261 as previously used (Markovic et al., 2009) were cultured in
DMEM containing MEM non-essential amino acids (1x), 1:100
Penicillin-Streptomycin solution (all Life Technologies) and 10%
FCS (Biochrome) and medium was changed every 2 days. Cell
cultures were maintained in the incubator at 37◦C in humidified
and 5% CO2-conditioned atmosphere; cells were passaged when
the cell density in the flask reached 80% confluence.
Animal Model
All experiments were performed in compliance with the National
Guidelines for Animal Protection, Germany, with approval of the
local animal care committee of the Government of Oberbayern
(Regierung von Oberbayern), and overseen by a veterinarian.
Eight week old C57BL/6 mice were obtained from Charles
River (Sulzfeld, Germany) and acclimated for 1 week. A first
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set of animal experiments was performed to analyze standard
PET parameters and to determine optimal parameters for BTV
measurements: At day 0, the mice were inoculated either with
50,000 GL261 cells suspended in 1µL of saline (GBM mice,
n = 15) or with 1µL of saline for control (sham mice, n = 6).
For inoculation, mice were anesthetized with i. p. injections of
approximately 100mg/kg ketamine 10% and 10mg/kg xylazine
2% in 0.9% NaCl. Anesthetized mice were immobilized and
mounted onto a stereotactic head holder (Kopf Instruments)
in the flat-skull position. After surface disinfection with 7.5%
Braunol solution (Braun) the skin of the skull was dissected with
a scalpel blade. One millimeter anterior and 1.5mm right to the
bregma, the skull was carefully drilled with a 23-gauge needle tip.
By stereotactic injection, 5 × 104 cells or 1µL PBS only applied
with a 22-gauge Hamilton syringe (Hamilton Bonaduz,) 5mm
below the drill hole in the calvarium. Cells were slowly injected
within 2min and after a settling period of another minute the
needle was removed in 1mm steps per minute. After that, the
wound was closed by suturing. Postoperative analgesia consisted
of 100µL of a 0.2% (w/v)-meloxicam solution i. p. while the mice
were kept warm.
A second set of animal experiments was used to test
the optimized parameters for BTV estimation: N = 15
supplementary GBM-bearing mice received PET scans and were
all sacrificed for autoradiography and histology immediately after
PET (n = 3 in week-3 and n = 4 in each week-2, -4, and -5).
Study Design
The GBM-bearing mice in the first set of animal experiments
received weekly PET scans beginning with week-2 after
inoculation. In addition, 3 shams were scanned in week-2 and
1 sham in each week-3, week-4, and week-5, irrespective of the
longitudinal setup for GBM-bearing mice. Every week, three
of the GBM-bearing mice and one corresponding sham were
sacrificed for autoradiography and histology immediately after
receiving the PET scan. The study was planned to end in week-
6 with the last 3 GBM-bearing mice being sacrificed. A study
overview is given in Table 1.
PET
Mice received bolus injection of 14.7 ± 2.3 MBq of [18F]-
FET in 150µL of saline into the tail vein. [18F]-FET was used
from clinical routine production (PET NET, Erlangen, Germany)
as previously described (Wester et al., 1999). If not specified
further, anesthesia was performed with isoflurane 1.5% delivered
via a mask at 3.5 L/min in oxygen. Following placement in
the tomograph (Siemens Inveon DPET), emission recording for
the interval 0–40min post injection (p. i.) followed by a 7min
transmission scan was obtained using a rotating [57Co] point
source. The image reconstruction procedure consisted of three-
dimensional ordered subset expectation maximization (OSEM)
with four iterations and 12 subsets followed by a maximum
a posteriori (MAP) algorithm with 32 iterations. Scatter and
attenuation correction were performed and a decay correction
for [18F] was applied. Frame setting consisted of two 20min
frames from which the latter (20–40min post injection) was
used for further analyses. The final voxel dimension of 0.39 ×
0.39 × 0.80mm was obtained by using a zoom factor of 1.0 and
a 256 × 256 × 159 matrix. Manual rigid-body co-registration of
PET images to a 3Tmagnetic resonance imaging (MRI) template,
followed by manual rigid-body re-alignment of intra-individual
longitudinal images, was accomplished using the PMOD fusion
tool (version 3.4; PMOD Technologies Ltd.; Rominger et al.,
2013).
For VOI-based analysis, a universal VOI of 123mm3 placed in
the tumor-free contralateral hemisphere was set as background
(BG) and a target VOI of 88mm3 surrounding the stereotactic
coordinates of the tumor in the right hemisphere served as
universal tumor VOI (Figure 1A).
In a second approach, individual tumor VOIs were
automatically drawn threshold-based and compared to the
individual histology volume.
Image analysis comprised assessment of the mean
standardized uptake value (SUVmean) and the maximal
standardized uptake value (SUVmax) for both the universal and
individual tumor VOI, each corrected for mean background
activity (SUVmean/BG; SUVmax/BG).
Autoradiography and Histology
Ex vivo autoradiography was performed immediately after
acquisition of PET data. Mice received intracardiac perfusion
with PBS to wash out the blood followed by intracardiac
perfusion with 4% PFA to fix the brain tissue (death within
65min p. i.). The dissected brains, placed in a base mold
and completely surrounded by cryo-matrix, were cooled
down for <5min in a −80◦C refrigerator, then frozen for
approximately 10 more min at −20◦C in a Leica CM 1510-
1 Cryostat (Leica Microsystems, Nussloch, Germany) and cut
in 16µm thick horizontal sections. Every 24th section was
mounted on glass slides within 75min post mortem. An
imaging plate (Fujifilm; BAS cassette2 2025) was exposed
to the slides for 15 h, scanned at 25µm resolution with
Raytest equipment (CR 35 BIO, Dürr Medical, Germany),
and analyzed with AIDA image analyzing software (V4.50).
Regions of interest (ROIs) were manually drawn around the
tumor and in the tumor-free contralateral hemisphere, and
mean radioactivity concentrations permg tissue equivalent
were used for calculation of autoradiographic SUVmean/BG
(mean of >15 slices per animal). Error-(%) in uncorrected
and PVE-corrected in vivo PET results was calculated relative
to this high resolution reference of autoradiographic results
ex vivo.
All sections were subsequently processed by Hematoxylin
and Eosin (HE) staining for histological analyses, either directly
after autoradiography or after being temporary stored at −80◦C.
Overview photographs (see Figure 2) of the tumors were taken
with a 3-CCD color video camera (Sony, Tokyo, Japan) attached
to an Axioskop 2 microscope (Zeiss, Jena, Germany) with an
1.25x (0.04NA) PlanApo N objective lens (Olympus, Japan).
ImageJ (National Institutes of Health, USA) was used to draw
the ROIs and to determine their area (see Figure 2C). Histologic
tumor volumes were estimated according to the Cavalieri method
on the basis of manually drawn tumor ROIs on every 24th
section.
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TABLE 1 | Modality overview.
[18F]-FET PET schedule [18F]-FET PET performed Histology/AR performed
GBM sham GBM sham GBM sham
Week-2 15 3 14 3 3 (0) 1
Week-3 12 1 11 1 2 (2) 1
Week-4 9 1 6 1 3 (3) 1
Week-5 6 1 6 1 4 (3) 1
Week-6 3 1 0 0 0 0
The middle row lists the effectively generated PET data per week as opposed to the previously intended PET schedule defined by the study design (shown in left row). The amount
of effectively generated histologies/autoradiographies for comparison with PET data is specified in the right row. Number of GBM mice with confirmed tumor in histology is bracketed.
AR = autoradiography.
FIGURE 1 | (A) A three-dimensional impression of both the universal tumor VOI surrounding the stereotactic coordinates (V = 88mm3, upper row) and the
background VOI placed in the tumor-free contralateral hemisphere (V = 123mm3, lower row) is given. (B) Eight region VOI-mask used for PVEC. The “optimal”
individual tumor VOI of this representative mouse (resulting from BTV analyses) is colored.
PVEC
PVEC was performed as described previously (Brendel et al.,
2014) and adjusted for the GBM mouse model. PVEC was
applied to eight GBM mice with confirmed tumor uptake in
autoradiography. In particular, we used a VOI-based approach
implemented in PMOD (Rousset et al., 1998, 2008) with a full-
width-at-half-maximum (FWHM) of 1.20 × 1.20 × 1.72mm, as
evaluated by a stab phantom for the current experimental setup.
A VOI-mask containing eight volumes (Figure 1B) was designed
for each mouse and consisted of the “optimal” individual tumor
VOI (resulting from BTV analyses) and a VOI comprising
the rest of the cerebrum, along with an additional six extra-
cerebral VOIs (Harderian glands, frontal, superior, basal, spinal,
and background). Thus, the main difference of our adjusted
approach as compared to application of PVEC in the Alzheimer’s
Disease model (Brendel et al., 2014) consists in the use of
different VOI masks for each individual GBM mouse instead
of a single standardized mask for the Alzheimer’s Disease
mice. Regional point spread functions were calculated through
integration of single tissue domains’ point spread function and
used for computation of weighting factors representing the
contributions of the set of eight tissue domains. Coefficients
of a geometric transfer matrix (GTM) were calculated, and
PVE-corrected radioactivity concentrations were calculated in
the defined VOIs by multiplication of the original PET
data by the inverted GTM. The PVE-corrected images thus
contained only those regions with VOI-mask definitions for
comparison with VOI-based results for uncorrected PET data.
Finally, VOIs were employed for calculation of PVE-corrected
SUVmean/BG.
BTV
For BTV estimation, a threshold-based VOI assignment was
performed. By a range of several thresholds (SUV/BG: ≥1.4;
≥1.6; ≥1.8; ≥2.0) voxels exceeding the respective threshold were
included in individual tumor VOIs. For each tumor four different
threshold-based PET volumes derived from this calculation and
were compared to the histologically determined tumor volume.
Additionally, the “optimal” threshold leading to the respective
histological tumor volume was determined. To this end, a
threshold approximation by using hot 3D VOI assignment was
applied until the most appropriate volume was reached. The
threshold with highest congruence between PET and histology
volumes was defined as “optimal” individual threshold. The
resulting VOI was defined as the “optimal” individual tumor
VOI (and implemented in the VOI-mask for PVEC as described
above). The shape of this “optimal” individual tumor VOI
was visually compared to the tumor shape in histology to
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FIGURE 2 | Hematoxylin and eosin (HE) stain. (A) Example of a mouse bearing a glioblastoma (GBM) at week-3 post injection. (B) Example of a sham operated
mouse at the same week-3. The injection site in the right hemisphere shows no histologic evidence for GBM growth or other tissue alterations. (C) Example of a
manually drawn region of interest (ROI) used for volume calculation according to the Cavalieri method.
preclude simple conformity of numerical volume values devoid
of geometrical congruence.
Statistics
Age-related group comparisons of PET results measured as
SUVmax/BG, SUVmean/BG and BTV were performed using
one-way ANOVA and the Tukey post-hoc test for multiple
comparisons, calculated by IBM SPSS 22 Statistics. For
correlation analyses, Pearson’s coefficients of correlation (ρ) were
calculated. The association between time and BTV progression
was characterized by applying linear, logarithmic, and quadratic
regression analyses as implemented in SPSS. The best curve
fitting model was determined by the highest ρ-value. A threshold
of p < 0.05 was considered to be significant.
RESULTS
Animal Model, Study Design, and Visual
Assessment
In the course of the study, a total of 43 PET scans was carried
out (n = 17 in week 2; n = 12 in week 3; n = 7 in week 4;
n = 7 in week 5; Table 1). All mice, except two, presented PET-
positive tumors at week-3 (9/9), week-4 (5/5), and week-5 (5/5),
whereas at week-2 only 25% (3/12) of the animals already had a
PET-positive GBM. The two mice where the tumor cells did not
grow were excluded from further statistical analysis.
All histologically confirmed tumors could be visually located
and clearly demarcated from healthy brain tissue, just as
evolution in size and signal strength could be visually tracked
over time with PET (Figure 3). No significant PET signal was
observed in shammice when visually comparing the injected side
against contralateral. A PET-corresponding autoradiography and
histology could be generated for n = 2 GBM mice and n = 1
sham in week-3, for n = 4 GBMmice and n = 1 sham in week-5
as well as for n = 3 GBM mice and n = 1 sham in both week-2
and week-4.
PET (Universal Tumor VOI)
Using the universal tumor VOI for assessment of tracer uptake,
the mean SUVmean/BG for GBM mice was 1.22 ± 0.14 at week-
2, increased to 1.45 ± 0.41 (p = n. s.) at week-3, and 1.40 ± 0.28
(p= n. s.) at week-4, finally mounting to 1.78± 0.29 (p < 0.005)
at week-5. Compared to the group of shams (1.15 ± 0.04), the
increase of mean SUVmean/BG was +6% at week 2, +26% at
week 3, +22% at week 4, and +55% at week 5 (Figure 4A).
SUVmax/BG in the GBM mice continually increased over time
starting with a mean of 1.92 ± 0.57 at week-2, reaching 2.11 ±
0.87 (p = n. s.) at week-3, 2.62 ± 0.76 (p = n. s.) at week-4, and
3.18 ± 0.80 (p < 0.05) at week-5. In relation to the SUVmax/BG
of 1.79 ± 0.26 in the group of shams, the increase was +8%
(week-2), +34% (week-3), +46% (week-4), and +77% (week-5;
Figure 4B).
In 3/43 scans a relevant spill-in from bone (all frontobasal)
influenced SUVmax/BG in the universal target VOI, such that
a manual masking was necessary. SUVmax/BG of the tumor
was clearly discriminable from spill-in for all those cases, as the
spill-in was unexceptionally located at the very edge of the VOI.
PVEC
Compared to the “gold standard” of ex vivo autoradiography,
SUVmean/BG was assessed by uncorrected PET with an error
of −26%. Meanwhile, the error of PET as compared to ex
vivo autoradiography could be diminished to less than the half
(−11%) by applying PVEC as previously described. Figure 5
gives a visual impression of PVEC by opposing both ex
vivo autoradiography and a PVE-corrected PET image to an
uncorrected PET image of a representative GBMmouse at week-
5 post operationem.
BTV Estimation
Threshold Analysis for BTV Definition
Figure 6A shows the results of BTV estimation by semi-
automatic (predefined) threshold-based VOI calculation in eight
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FIGURE 3 | Example of longitudinal [18F]-FET µPET for in vivo monitoring of glioma growth. (A) Week-2 (B) week-3 (C) week-4 (D) week-5 post
operationem. SUV/BG (scale bar) is projected on horizontal slices of the mouse brain atlas.
FIGURE 4 | [18F]-FET uptake as assessed by PET using the universal tumor VOI. The GBM-bearing mice are split in four groups depending on time; the
shams are summed up into one group. (A) mean SUVmean/BG ± SD (B) mean SUVmax/BG ± SD. *p < 0.05; **p < 0.01.
mice with PET-positive tumor and comparison of BTV to their
individual histology volume serving as reference. Except two
estimations with an acceptable error <5%, all estimated BTVs
clearly didn’t match with the histology reference. Using 1.4 as
threshold factor, only one tumor volume has been estimated
with an acceptable error (−5%), while three tumor volumes
have been clearly underestimated and four volumes clearly
overestimated, two of them considerably (+89, +95%). Using
1.6 as threshold factor, one volume has been overestimated
with +8% and three have been clearly overestimated, whereas
two volumes have been clearly underestimated, in particular
one of them (−87%). Using 1.8 as threshold factor, all
volumes—except one accurate estimation with +4% of error—
have been clearly underestimated, three of them very highly
(−86, −96, −86%). Finally using 2.0 as threshold factor,
all the volumes have been clearly underestimated with none
of them providing an acceptable estimation of the histology
volume.
Therefore, none of these pre-fixed threshold factors qualified
to serve as unique standardized threshold for BTV estimation
(indicated by high root-mean-square error up to 200%,
Figure 6B), even if one of the thresholds might be suitable for
BTV estimation in some individual case.
Subsequently we investigated individual thresholds for BTV
definition using the histology volume as reference, which showed
a high variability between the animals (range 1.27–1.83). Hence,
no universal threshold for “optimal” volume estimation could be
identified.
The “optimal” individual threshold did not correlate with
the histology volume (ρ = −0.07, p = n. s., Figure 7A), but
showed a rather strong positive correlation with SUVmean/BG
(ρ = 0.81; p < 0.05, Figure 7B) and ultimately revealed a
nearly perfect positive correlation with SUVmax/BG (ρ = 0.97,
p < 0.001, Figure 7C). Being aware of PVE we excluded a
strong dependency of PET estimates from the histology-based
volume which gave no significant association for SUVmean/BG
(ρ = 0.43; p = n. s.) and especially SUVmax/BG (ρ = 0.11;
p = n. s., Figure 7D). The determined VOI shape in PET closely
matched to the boundaries obtained from histology (Figure 7E).
The linear association between SUVmax/BG (x) derived from
uptake analysis in the universal tumor VOI and the “optimal“
individual threshold (y) can be expressed by Equation (1) and
was consecutively used to obtain BTV in all mice with a detected
tumor in PET.
y = 0.3215x+ 0.5654 (1)
Longitudinal BTV
The individual threshold-based method of BTV assessment was
applied to the whole dataset and tested with regard to plausibility
of longitudinal results and visual control of the resulting
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FIGURE 5 | Comparison of uncorrected [18F]-FET PET (upper row, A), PVE-corrected PET (lower row, B) and corresponding ex vivo autoradiography
(C) of a representative GBM mouse at week-5 post operationem. PET images were scaled to contralateral tumor-free background and overlain on a 3T MRI
mouse template. PVEC was performed with an eight region mask. Error-(%) ± SD of uncorrected (dark bar) and PVE-corrected (light bar) data vs. ex vivo
autoradiography are shown for the whole group of GBM mice (D).
FIGURE 6 | Biological tumor volume (BTV) as estimated by predefined thresholds deviates from the histology reference volume. (A) Percentage relation
of BTV and histology volume is shown for eight mice individually. (B) The root-mean-square error for the entire group of mice is shown for each pre-fixed threshold
separately.
individual tumor VOIs (Figure 7E). BTV showed increasing
tumor volume with time, starting at week-2 (mean 6.7mm3;
range 0–35.1mm3), increasing to a mean BTV of 33.7mm3 at
week-3 (range 7.7–57.5mm3, p = 0.12), further developing
to a mean BTV of 58.3mm3 at week-4 (range 24.2–86.3mm3,
p < 0.005) and finally terminating at a mean BTV of 82.6mm3
at week-5 (range 38.2–145.7mm3, p < 0.001; Figure 8A).
The mean increase for all longitudinally assessed volumes was
33.7mm3 per week, however best described by a quadratic fit
(ρ = 0.77; p < 0.001) that indicated faster progression of BTV
at the later stages (Figure 8B).
After application of individual tumor VOIs for the assessment
of tracer uptake, 13% (±12%) higher SUVmean/BG values were
obtained for the GBM mice with a PET-positive tumor: Mean
SUVmean/BG for GBM mice resulted at 1.28 ± 0.32 at week-2,
increased to 1.62 ± 0.52 (p = n. s.) at week-3, and 1.66 ± 0.41
(p = n. s.) at week-4, finally mounting to 1.96 ± 0.34 (p < 0.01)
at week-5.
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FIGURE 7 | The individual “optimal” threshold does not correlate with the tumor volume as assessed by histology (A, ρ = −0.07, p = n. s.), but shows a
strong positive correlation with SUVmean/BG (B, ρ = 0.81; p < 0.05) and especially with SUVmax/BG (C, ρ = 0.97, p < 0.001). The latter however doesn’t
seem to be dependent on the tumor volume as assessed by histology (D, ρ = 0.11; p = n. s.). The high congruency between H&E tumor volume and in BTV as
defined by the individual “optimal” threshold is illustrated by an image overlay of PET and histology for the tumor of a representative GBM mouse (E).
SUVmax/BG remained equal after application of
individual tumor VOIs. In all mice the supposed tumor
edge in PET was captured adequately by a visual control
and gave a reasonable differentiation between tumor and
background.
Validation Study
In accordance with the first experimental round, nearly all mice
of the validation round presented PET-positive tumors at week-3
(2/3), week-4 (4/4), and week-5 (4/4), but not at week-2 (0/4).
The results of BTV estimation with standardized thresholds
(SUV/BG: ≥1.4; ≥1.6; ≥1.8; ≥2.0; n = 15) were consistent
with the results of the primary study and delivered strongly
unreliable BTVs in comparison to the histological reference
volumes (Figure 9A).
Finally, Equation (1) (see Section Threshold Analysis for BTV
Definition) was applied to all n = 15 mice of the validation
cohort in order to verify the new SUVmax/BG-based method
for individual BTV estimation described above. The resulting
individual thresholds led to some highly accurate BTVs (n =
9/15 mice had a deviation of <7mm3 compared to histology
volume) and the overall correlation of BTV estimates to the
histology reference volumes was strong in the validation cohort
(ρ = 0.88, p < 0.01, Figure 9B). Some higher deviations in BTV
estimation were observed in larger tumors.
DISCUSSION
In the present multimodal study, we tested different approaches
to perform in vivo imaging with small animal [18F]-FET PET
in an orthotopic glioblastoma mouse model. In addition to
assessment of SUVmax/BG and SUVmean/BG, which show
a high inter-individual variability and do not correlate with
the actual tumor size, we used for the first time threshold-
based approaches including several thresholds to determine
the BTV in the GBM mouse model. As a major finding, we
revealed the common clinical approach of BTV estimation
(using standardized thresholds) to be unreliable for volumetric
in vivo monitoring of tumor growth with [18F]-FET PET—
at least in this GBM mouse model. In addition, we propose
a histology-verified method using individual thresholds which
improved BTV estimation in comparison to the standard
method.
Animal Model and Study Design
With the initial objective to improve imaging techniques
potentially able to survey the response of experimental glioma
therapies, we chose the isogenic GL261 cell line (transplanted
into C57BL/6 mice) serving as an orthotopic murine brain
tumor model, since GL261 is most widely used for the
investigation of various antitumoral therapies including gene
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FIGURE 8 | Progression of BTV in PET as defined by the individual threshold shown as mean BTV per week (A) and furthermore illustrated for each
mouse individually together with the mean longitudinal BTV in terms of a quadratic fit (B). *p < 0.05; ***p < 0.001.
FIGURE 9 | Validation study. (A) Percentage relation of BTV and histology volume for predefined thresholds is shown for 10 tumor-bearing mice individually. (B) BTV
as defined by the new method using SUVmax/BG-based individual thresholds shows a strong correlation with the histology reference volume (n = 15, ρ = 0.88,
p < 0.01).
therapy, immunotherapy or antiangiogenic therapy (Szatmari
et al., 2006; Stock et al., 2012).
We included sham-controls for each discrete time point in
the study design and observed no [18F]-FET PET signal in the
tumor-free brain.
Based on the short time between acquisition of PET scans
and subsequent brain fixation by intracardiac perfusion, we
supposed a high correspondency between PET, histology, and ex
vivo autoradiography and assumed their direct comparison to be
highly convenient. It has to be noted, that the histologic volume
assessment has itself some limitations too—slices can for example
shrink during the tissue preparation.
Feasibility, Time Window, and
Co-Registration
Our data approved general feasibility of [18F]-FET imaging using
PET in a GBM mouse model. The scanning procedure in its
longitudinal setup was well-tolerated by the glioma-bearing mice
and provided a copious supply of exploitable PET data.
With a view to our initial targets, e.g. BTV estimation, we
opted to concentrate in this study on static PET analyses. Pre-
clinical glioma research is short on experience regarding adequate
time frame setting in [18F]-FET PET. Hence, we decided to adopt
the time frame from the clinical protocol in glioma patients (20–
40min p. i.; Popperl et al., 2006) and approved its translation to
our mouse model—as well as the accurate amount of [18F]-FET
to inject in mice—by previous pilot scans.
An automatic co-registration would facilitate the most
favorable approach for spatial normalization as it as well ensures
user independence. Indeed we tried an automatized brain
normalization method in PMOD with established parameter of
our group (Overhoff et al., 2016). However, as [18F]-PET has a
relatively low uptake in the not-tumor-affected brain we observed
a significant influence of the higher and variable extracerebral
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uptake on results of the automatic approach. Up to now the
results were not satisfactory enough to introduce this method to
the work-flow and we circumvented this issue by blinding the
mice to the reader and used a fine realignment of individual mice
to their baseline. Visual inspection of the resulting manually co-
registered images gave good fits to the brain borders of the MRI
mouse atlas and should serve as a precise method.
Visual Examination
According to our results, in vivo monitoring of the inoculated
tumor is feasible with longitudinal [18F]-FET PET by simple
means of visual examination as a first simplistic and reader-
dependent approach (Figure 3). PET-positive tumors were found
in 25% of the GBM mice examined in the second week; negative
reads were confirmed by negative histology (3/3 negative). The
smallest histologically verified tumor (19mm3, week-3) was
easily identifiable by a visual read such as the smallest assessed
tumor by the BTV threshold method (7mm3, week-3). These
results are consistent with [18F]-FET being a highly sensitive
biomarker for glioma tissue leading to a sharp contrast between
tumor and healthy background. However, as a matter of course,
quantification is mandatory to objectify previous findings and
enable a reader-independent consideration of tumoral lesions
and growth monitoring with [18F]-FET PET. This turns out to
be especially important, when even slight differences in uptake
behavior or tumor size—e.g. in the context of therapy studies—
have to be distinguished.
Definition and Limitations of Standardized
VOIs
According to the common approach, we first determined
SUVmax and SUVmean in a predefined uniform target VOI
surrounding the tumor and corrected both values for healthy
background (i.e., SUVmean of the tumor-free VOI in the
contralateral hemisphere). At this point, the dimensions of
our chosen tumor-free background VOI (123mm3, Figure 1A)
deserve particular notice, since it overpasses other reported
background VOIs 30 times in size and therefore guarantees
a reliable background quantification (Nedergaard et al., 2014,
2015). Due to this extent, activity fluctuations in healthy brain
tissue as well as single accidental voxels of bone spill-in (since
[18F] itself is known to accumulate in the cranium to a
certain extent; Mille et al., 2012) shouldn’t have remarkable
consequences on the background’s SUVmean.
The above-sketched approach (using standardized target
VOIs) is reasonable for assessment of SUVmax/BG since the
universal tumor VOI should compromise the entire tumor and
consequently the voxel with maximum [18F]-FET uptake. Care
has to be taken when mice exhibit such relevant bone uptake
that the universal target VOI gets contaminated, which was the
case in 3/43 scans. Since a single contaminated voxel determines
an overestimated SUVmax/BG we recommend manual control
slice-by-slice, which is easily feasible by a screening ROI/VOI
for the maximum uptake. This is essential when SUVmax/BG
is considered for the definition of individual thresholds for
BTV assessment. However, in all three contaminated cases the
maximum related to the tumor was clearly distinguishable from
the maximum spill-in from bone and therefore we do not
see a major limitation caused by this issue. The assessment of
SUVmean/BG implicates limitations since a universal tumor VOI
doesn’t account for the different tumor sizes, but the related
SUVmean/BG however accounts for every compromised voxel
in equal measure. Thus, SUVmean/BG will be underestimated
in small tumors due to a relatively high portion of healthy brain
tissue comprised by the large universal VOI. Our universal target
VOI after all embraces advanced gliomas but therefore doesn’t
come up in an optimum way to the smaller ones.
Uptake Analyses
The standard PET parameters show a clear temporal progress
in gliomas in this mouse model (Figure 4). We interpret this
finding as naturally related to tumor development and as being
on this note typical for the evolution of tumoral [18F]-FET
uptake with time as well in human data. However, it should be
noticed well that the pathophysiological contributions leading
to an elevated peak (SUVmax/BG) or global (SUVmean/BG)
tumor uptake of [18F]-FET are not fully understood and are
probably caused multifactorial by the molecular features of the
tumor cells. Indeed we find an inter-individually heterogeneous
[18F]-FET uptake in this cohort of mice, with some animals
bearing high uptake tumors even at week-2 post operationem and
others that indicate a slow development of low uptake tumors
over the whole longitudinal setup. The heterogeneity is further
boosted by independency of [18F]-FET uptake from tumor
sizes (Figure 7D), which implicates that large tumors do not
necessarily need to be characterized by a high tumor uptake and
vice versa. This finding shows that measurement of SUV might
reflect molecular features of the tumor but not tumor growth
in terms of size, which would be of interest when evaluating
treatment responses. The reason for this inter-individual uptake
variability of SUVmax/BG and SUVmean/BG remains to be
investigated, but surely the heterogeneity represents a chance
for better understanding the functionality of [18F]-FET uptake
by intensified basic research on [18F]-FET PET in GBM mouse
models.
In this context, the methodology itself should as well be
considered as a contributor to the heterogeneity as the above-
discussed insufficient fitting accuracy of the chosen universal
target VOI could potentially induce under- and overestimations
of [18F]-FET uptake values. Nonetheless even with application
of individual tumor VOIs to all mice (as discussed in more
detail below) the variance of SUVmean/BG did not decrease
and indicated that the heterogeneity is rather a natural feature
of the model but not a methodological bias. This and the
finding, that the SUV parameters did not correlate with the
actual tumor volume, emphasizes even more that stand alone
SUVmax/BG or SUVmean/BG assessments are not ideal for
in vivo characterization of glioblastoma as they do not reflect all
important in vivo information of the tumor.
PVEC
By applying PVEC to our PET data, we succeeded to improve
accuracy of [18F]-FET PET by shortening the gap between PET
and autoradiography findings which are caused by the limited
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resolution of the PET scanner (Visser et al., 2009). Despite
decreasing errors of SUVmean/BG by this method, it has to be
considered that only a tumoral and a background SUV/BG result
after PVEC, which limits regional analyses.
BTV
As a major finding of this study, we revealed the common clinical
approach of semi-automatic threshold-based BTV estimation
by [18F]-FET PET to deliver apparently inconsistent results
when correlated with the gold standard histology volume—at
least in the present GBM mouse model (Figure 6). It was by
intention, that we included the thresholds previously used in
the clinical field for BTV estimation (Jansen et al., 2012b, 2013;
Suchorska et al., 2015) in our analyses, however none of those
pre-fixed thresholds was suitable to mirror PET-based BTVs
consistently with the tumor volume as assessed by histology.
As human studies hardly have the possibility to assess the
“real” BTV by gold standard histology assessment directly after
imaging, we want to emphasize the value of pre-clinical studies
regarding such issues. Human studies have compared PET-
derived BTV to tumor volumes on MRI and have reported
substantial discrepancies between both imaging methods (Ewelt
et al., 2011; Niyazi et al., 2011; Suchorska et al., 2015). A limitation
of our study is the lacking µMRI, which would have facilitated a
direct comparison of functional and structural imaging methods
for BTV estimation. Nonetheless, there are only few facilities
that have the opportunity of pre-clinical hybrid imaging (serial
or simultaneously) so far, clearly justifying current stand-
alone µPET investigations. Furthermore, numerous studies have
revealed that the delineation of vital tumor tissue is better with
[18F]-FET PET than MRI in glioma patients, particularly after
multimodal treatment involving treatment-induced changes on
MRI which cannot be accurately differentiated from tumor tissue
(Galldiks et al., 2012b, 2013a,b, 2015a; Jansen et al., 2013).
Since the common approach for BTV estimation with [18F]-
FET PET after all did not seem to be appropriate for the GBM
mouse model, we determined the “optimal” individual threshold
for BTV definition using the histology volume as reference
for each mouse. These thresholds showed a high variability,
but surprisingly, SUVmax/BG correlated nearly perfectly with
these individual thresholds (Figure 7C). We excluded partial
volume effects as the key actor of the correlation as neither
SUVmax/BG nor the individual threshold seem to depend on the
histology tumor volume (Figures 7A,D). Thus, the SUVmax/BG
might adequately resemble the magnitude of [18F]-FET uptake
in the majority of tumor cells in the individual mouse, including
those cells at the tumor’s edge, and thereby determine the
threshold between tumor and healthy brain tissue.We conducted
a subsequent validation study with twice the number of mice
(n = 15) to test the reproducibility of our novel approach.
Altogether, the method led to accurate BTV estimations in both
rounds (total n = 23), which, again, was clearly superior to
the BTV estimation using predefined thresholds. Some outliers
in large scaled tumors might limit the method with regard to
accuracy in very large volumes. Nonetheless, the method strongly
improved BTV estimation when compared to the standard
approach (using standardized thresholds) and mainly delivered
accurate approximations of histology volume for this stand-alone
µPET approach.
Besides various thresholding-approaches, shape-based
approaches as well have been investigated for BTV definition
in rodent tumor models: Wu et al. described—amongst three
different threshold-based approaches—an edge-detection-based
automated contouring system for definition of BTV using
[18F]-FDG PET in mammary tumors (grown in Lewis rats). In
contrary to their threshold-based approaches, the shape-based
system failed to produce reliable volumes in comparison to the
histology volume due to the system’s lack of reproducibility (Wu
et al., 2015). However, we share the author’s opinion on the
relevance of edge detection methods: In this study, we do not
provide a shape-based method, but—on this note—controlled
the shape of every PET-delineated volume resulting from our
individual method with the tumor shape in histology and
revealed both shapes to closely match.
Although [18F]-FET is the most established tracer for
molecular glioma imaging in the clinical field, other tracers have
shown promising results for delineation of BTV in the pre-
clinical field as well: 11C-methylaminoisobutyric acid ([11C]-
MeAIB) has for example been used in a double tracer study
together with [18F]-FDG to estimate tumor volumes in two
phenotypically different orthotopic GBM rat models. [11C]-
MeAIB PET was accurate for volume estimation in non-
infiltrating brain tumors when compared to histologic findings,
proved however to be hardly reproducible in highly infiltrating
brain tumors (Halle et al., 2015).
As in our study, the authors primarily focused on thresholding
methods, which are the most commonly used methods for image
segmentation in regard to volume estimation. It would be of
interest for future studies, to investigate how less commonly
used segmentation methods, using e. g. edge detection, region
growing, clustering, stochastic models, deformable models, or
classifiers (Zaidi and El Naqa, 2010), could be used to improve
the results of our new approach.
CONCLUSIONS
[18F]-FET PET is feasible for glioma imaging in the GBM mouse
model. Standard PET parameters reflect tumor growth intra-
individually, but GL261 tumor cells show high inter-individual
uptake variability and standard uptake values do not correlate
with tumor size. PVEC is beneficial to improve accuracy of [18F]-
FET PET by reducing the error of SUVmean/BG as assessed by
PET in comparison to ex vivo autoradiography. Standardized
thresholds respective to the common approach seem to be
inappropriate for BTV estimation in gliomas—at least in the
present glioblastoma mouse model. Individualized thresholds on
the contrary seem to be more appropriate for volumetric in vivo
monitoring of tumor growth with [18F]-FET PET.
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